IR@PKUHSC  > 北京大学第一临床医学院  > 心血管内科
学科主题临床医学
CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients
Chen, G1; Jiang, S1; Mao, G1; Zhang, S1; Hong, X1; Tang, G1; Li, Z1; Liu, X1; Zhang, Y1; Xing, H1; Wang, B1; Yu, Y1; Xu, X1
关键词Blood Pressure Cyp2c9 Gene Drug Concentration Gene Polymorphism Irbesartan Pharmacogenetics
刊名METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
2006
DOI10.1358/mf.200628.1.962773
28期:1页:19-24
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]II RECEPTOR ANTAGONIST ; GENETIC-POLYMORPHISM ; LIVER-MICROSOMES ; ALLELIC VARIANTS ; CYP2C9 ; POPULATION ; CYP2C9-ASTERISK-3 ; CYTOCHROME-P450 ; WARFARIN ; ASSOCIATION
英文摘要

Our previous study demonstrated that the CYP2C9*3 gene variant was significantly associated with elevated plasma irbesartan concentration and blood pressure decline, assessed by a 4-week follow-up and revisit following daily administration of irbesartan. We conducted a further analysis to examine the acute effects of the CYP2C9 polymorphism on plasma concentration and blood pressure through remeasurement 6 h after administration of irbesartan. We used an extreme-sampling approach by selecting individuals from the top and bottom deciles of blood pressure response residuals to irbesartan from the previous study population in Anhui, Taihu, and Dongzhi Counties, in China. A total of 196 subjects were available for the analysis. Pre- and posttreatment systolic and diastolic blood pressures (SBP and DBP), and venous blood samples (0.5, 2, and 6 h following the first treatment) were collected from each individual. Plasma irbesartan concentrations were determined by a standard HPLC/fluorescence method. the observed frequencies were 97.7% for CYP2C9*1 (Ile358) and 2.3% for CYP2C9*3 (Leu359). Subjects with the CYP2C9*1/CYP2C9*3 genotype had significantly higher plasma irbesartan concentrations when compared with those with the CYP2C9*1/CYP2C9*1 genotype (beta +/- SE = 81 +/- 36) and greater DBP response (beta +/- SE = 5.6 +/- 2.5 mmHg) at the 6-h time point after adjusting for important confounders. Our finding suggests that the CYP2C9*3 gene variant significantly alters the plasma concentration and acute DBP response at the 6-h point following irbesartan treatment in Chinese hypertensive patients. (C) 2006 Prous Science. All rights reserved.

语种英语
WOS记录号WOS:000236340900004
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53119
专题北京大学第一临床医学院_心血管内科
作者单位1.Anhui Coll Tradit Chinese Med, Dept Pharmacol, Hefei, Peoples R China
2.Anhui Med Univ, Inst Biomed, Hefei 230032, Anhui, Peoples R China
3.Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China
4.Peking Univ, Hosp 1, Dept Cardiovasc Dis, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Chen, G,Jiang, S,Mao, G,et al. CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients[J]. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY,2006,28(1):19-24.
APA Chen, G.,Jiang, S.,Mao, G.,Zhang, S.,Hong, X.,...&Xu, X.(2006).CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients.METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY,28(1),19-24.
MLA Chen, G,et al."CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients".METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 28.1(2006):19-24.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chen, G]的文章
[Jiang, S]的文章
[Mao, G]的文章
百度学术
百度学术中相似的文章
[Chen, G]的文章
[Jiang, S]的文章
[Mao, G]的文章
必应学术
必应学术中相似的文章
[Chen, G]的文章
[Jiang, S]的文章
[Mao, G]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。